Context Therapeutics Appoints Dr. Karen Smith As Interim Chief Medical Officer Amid Executive Transition

Context Therapeutics Inc., a biopharmaceutical company developing T cell-engaging bispecific antibodies for solid tumours, has appointed Dr. Karen Smith as interim Chief Medical Officer (CMO). Dr. Smith succeeds Dr. Claudio Dansky Ullmann, who is stepping down from the company as of May 10, 2025. While Context searches for a permanent CMO, Dr. Smith will temporarily oversee clinical strategy and operations while continuing her service on the company’s Board of Directors.

“As we take the next steps in advancing our pipeline, I am delighted to have Karen’s support and leadership. Karen’s experience in drug development will make her guidance invaluable through this transition. “I am grateful to Claudio for his contributions to Context,” said Martin Lehr, CEO of Context. 

Dr. Smith brings more than two decades of biopharmaceutical leadership to the role, with a strong track record in clinical development and drug commercialisation. She previously served as Global Head of R&D and CMO at Jazz Pharmaceuticals and held senior positions at Allergan, AstraZeneca, and Bristol Myers Squibb.